# Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

> **NCT05433532** · PHASE2 · COMPLETED · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 20 (actual)

## Conditions studied

- Philadelphia Chromosome
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemia
- Mixed Phenotype Acute Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **DRUG:** Flumatinib

## Key facts

- **NCT ID:** NCT05433532
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-01
- **Primary completion:** 2024-04-13
- **Final completion:** 2024-04-13
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05433532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05433532, "Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05433532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*